IRIS Accounts Production v24.2.0.383 09473027 Board of Directors 1.1.23 31.12.23 31.12.23 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh094730272022-12-31094730272023-12-31094730272023-01-012023-12-31094730272021-12-31094730272022-01-012022-12-31094730272022-12-3109473027ns15:EnglandWales2023-01-012023-12-3109473027ns14:PoundSterling2023-01-012023-12-3109473027ns10:Director12023-01-012023-12-3109473027ns10:PrivateLimitedCompanyLtd2023-01-012023-12-3109473027ns10:SmallEntities2023-01-012023-12-3109473027ns10:AuditExempt-NoAccountantsReport2023-01-012023-12-3109473027ns10:SmallCompaniesRegimeForDirectorsReport2023-01-012023-12-3109473027ns10:SmallCompaniesRegimeForAccounts2023-01-012023-12-3109473027ns10:FullAccounts2023-01-012023-12-3109473027ns10:Director22023-01-012023-12-3109473027ns10:Director32023-01-012023-12-3109473027ns10:RegisteredOffice2023-01-012023-12-3109473027ns5:CurrentFinancialInstruments2023-12-3109473027ns5:CurrentFinancialInstruments2022-12-3109473027ns5:ShareCapital2023-12-3109473027ns5:ShareCapital2022-12-3109473027ns5:SharePremium2023-12-3109473027ns5:SharePremium2022-12-3109473027ns5:RetainedEarningsAccumulatedLosses2023-12-3109473027ns5:RetainedEarningsAccumulatedLosses2022-12-3109473027ns5:PlantMachinery2023-01-012023-12-3109473027ns5:PlantMachinery2022-12-3109473027ns5:PlantMachinery2023-12-3109473027ns5:PlantMachinery2022-12-3109473027ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-3109473027ns5:WithinOneYearns5:CurrentFinancialInstruments2022-12-31
REGISTERED NUMBER: 09473027 (England and Wales)















Unaudited Financial Statements for the Year Ended 31 December 2023

for

Evolution Biotechnologies Ltd

Evolution Biotechnologies Ltd (Registered number: 09473027)






Contents of the Financial Statements
for the Year Ended 31 December 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


Evolution Biotechnologies Ltd

Company Information
for the Year Ended 31 December 2023







DIRECTORS: Dr D R Harper
A Gunn
Dr M L McConville





REGISTERED OFFICE: Colworth Science Park
Sharnbrook
Bedford
Bedfordshire
MK44 1LZ





REGISTERED NUMBER: 09473027 (England and Wales)





ACCOUNTANTS: Godfrey Laws & Co Limited
1 Doolittle Yard
Froghall Road
Ampthill
Bedfordshire
MK45 2NW

Evolution Biotechnologies Ltd (Registered number: 09473027)

Balance Sheet
31 December 2023

31.12.23 31.12.22
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 436 683

CURRENT ASSETS
Debtors 5 2,823 936
Cash at bank 128 1,476
2,951 2,412
CREDITORS
Amounts falling due within one year 6 509,884 474,052
NET CURRENT LIABILITIES (506,933 ) (471,640 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(506,497

)

(470,957

)

CAPITAL AND RESERVES
Called up share capital 2,300 2,300
Share premium 149,700 149,700
Retained earnings (658,497 ) (622,957 )
SHAREHOLDERS' FUNDS (506,497 ) (470,957 )

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 16 September 2024 and were signed on its behalf by:





Dr D R Harper - Director


Evolution Biotechnologies Ltd (Registered number: 09473027)

Notes to the Financial Statements
for the Year Ended 31 December 2023

1. STATUTORY INFORMATION

Evolution Biotechnologies Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 33% on cost and 25% on reducing balance

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development
Expenditure on research and development is written off in the year in which it is incurred.


Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Going concern
The company's working capital requirements are funded by the directors. Although these loans are repayable on demand, the directors have indicated that these loans will continue for the foreseeable future.

The directors therefore continue to adopt the going concern basis in preparing these financial statements. This assumes that the company will continue in operation for the foreseeable future.

Evolution Biotechnologies Ltd (Registered number: 09473027)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2023

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2022 - 2 ) .

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 January 2023
and 31 December 2023 4,709
DEPRECIATION
At 1 January 2023 4,026
Charge for year 247
At 31 December 2023 4,273
NET BOOK VALUE
At 31 December 2023 436
At 31 December 2022 683

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.23 31.12.22
£    £   
Other debtors 2,823 936

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.23 31.12.22
£    £   
Bank loans and overdrafts 4,679 -
Trade creditors 61,295 57,262
Taxation and social security - 918
Other creditors 443,910 415,872
509,884 474,052

7. ULTIMATE CONTROLLING PARTY

The controlling party is Dr D R Harper.